SCHEMBL13627913

SCHEMBL13627913

Cc1cccc(CN2C(=O)/C(=N\O)c3cc([N+](=O)[O-])ccc32)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.56
CASP3 P42574 1/20 0.56
CASP4 P49662 1/20 0.56
CASP7 P55210 1/20 0.56
CASP9 P55211 1/20 0.56
CASP6 P55212 1/20 0.56
CASP8 Q14790 1/20 0.56
ALDH1A1 P00352 2/20 0.52
HPGD P15428 2/20 0.52
HTT P42858 2/20 0.52
MAPT P10636 8/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
LMNA P02545 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
APP P05067 6/20 0.43
SNCA P37840 6/20 0.43
HSP90AA1 P07900 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627912 0.88 MAPT (0.57) CASP1CASP3CASP4CASP7CASP9
SCHEMBL13627910 0.88 CASP1 (0.72) CASP1CASP3CASP4CASP7CASP9
SCHEMBL13627915 0.87 CASP1 (0.56) CASP1CASP3CASP4CASP7CASP9
SCHEMBL13627922 0.86 ACHE (0.48) ALDH1A1MAPTMEN1LMNAKMT2A
SCHEMBL13627920 0.86 MAPT (0.52) CASP1CASP3CASP4CASP7CASP9
SCHEMBL13627972 0.83 ALDH1A1 (0.57) CASP1CASP3CASP4CASP7CASP9
SCHEMBL13627887 0.82 MAPT (0.66) CASP1CASP3CASP4CASP7CASP9
SCHEMBL13627948 0.82 TRPA1 (0.48) ALDH1A1HPGDMAPTLMNAKMT2A
SCHEMBL13627933 0.82 TP53 (0.53) ALDH1A1MAPTLMNASMN1; SMN2POLB
SCHEMBL13627906 0.82 ALDH1A1 (0.52) ALDH1A1LMNAKMT2AACHECA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 CASP1 355/4885CASP3 178/4885CASP4 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.